Actinic keratosis (AK) is one of the most common skin disorders and can be a first step in the development of skin cancer. Patients undergoing conventional AK treatments frequently experience pain, bleeding, inflammation, and scarring. Consequently, new and better treatment options to reduce patient side effects such as skin damage are high demand. The Nordic biotech Coegin Pharma will soon start clinical evaluation of its candidate AVX001 as a potential new and better treatment of AK. BioStock was able to speak with the lead clinician in the clinical program, Professor Merete Hædersdal, to learn more about AK and Coegin Pharma's clinical development program.

Read the full interview with Merete Hædersdal at biostock.se:

https://www.biostock.se/en/coegin-pharmas-clinical-development-in-actinic-keratosis/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

https://news.cision.com/coegin-pharma-ab/r/biostock--coegin-pharma-s-clinical-development-in-actinic-keratosis,c3295025

(c) 2021 Cision. All rights reserved., source Press Releases - English